CD8

[Clinical Cancer Research] Investigators identified EP4 as a specific target for prostate cancer immunotherapy and demonstrated that YY001 inhibited the growth of prostate tumors by regulating the immune microenvironment and strongly synergized with anti-programmed cell death protein-1 antibodies.

[Cell Chemical Biology] To enable tumor-localized immunotherapy following intravenous administration, investigators chemically conjugated a polyspecific integrin-binding peptide (PIP) to an immunostimulant to generate a tumor-targeted immunomodulatory agent, referred to as PIP-CpG.

[Cancer Research] Researchers revealed that delivery of miR-122 was associated with downregulation of key genes in involved in metastatic and cancer inflammation pathways, including several pro-inflammatory factors, matrix metalloproteinases, and other extracellular matrix degradation enzymes.

[Cancer Research] The authors demonstrated that inhibition of fibroblast growth factor receptor 3 (FGFR3) in FGFR3-activated bladder cancer elevated PD-L1 protein levels by affecting its ubiquitination, thereby inhibiting the anti-tumor activity of CD8+ T cells.

[Advanced Science] Among various cell sources, FGL1/PD-L1 small extracellular vesicles (sEVs) derived from MSCs not only enriched FGL1/PD-L1 expression but also maintained the immunomodulatory properties of unmodified MSC sEVs.

[Frontiers in Endocrinology] The authors differentiated iPSC from one donor into dendritic cells, macrophages, endothelial cells, and β-cells, and engineered T cell avatars from the same donor to provide an in vitro platform to study genetic influences on critical cellular interactions.